We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Drug Development Stakeholders Call for Improved Pharmaceutical Testing

Drug Development Stakeholders Call for Improved Pharmaceutical Testing content piece image

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Drug Development Stakeholders Call for Improved Pharmaceutical Testing"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Drug development stakeholders from private and public sectors, including researchers, academics, and representatives from the pharmaceutical industry and advocacy groups, have joined together to call for a significant and urgent shift to prioritize predictive, human-based nonclinical tests. Published in Drug Discovery Today, "Advancing Nonclinical Innovation and Safety in Pharmaceutical Testing" identifies the necessary steps that will lead to safer and more effective medicines, guided by a greater focus on human-based in vitro and in silico methods, which allow scientists to observe human cells, tissues, and biological processes, and their interaction with potential medications.

Participants of the Nonclinical Innovation and Patient Safety Initiative call for increased funding for human-based approaches, new and improved guidelines for preserving human cells and tissues for research, additional training for scientists to use human-based tools, and regulation that does not favor animal-based research. Complementing the FDA's Predictive Toxicology Roadmap, the authors affirm that using human-relevant tests earlier in the testing process would result in reduced waste, cost, and animal use, as unsafe or ineffective treatments would fail sooner and potentially safe and effective drugs would not be abandoned as a result of falsely appearing to be toxic.

"The status quo of pharmaceutical testing is tragically wasteful, in terms of time, cost, and lives lost," says lead author Elizabeth Baker, Esq., pharmaceutical policy director with the Physicians Committee for Responsible Medicine. "This paper--and the ensuing collaboration--lays out thoughtful recommendations that have the potential to greatly improve drug development and save lives.."

This article has been republished from materials provided by Physicians Committee for Responsible Medicine. Note: material may have been edited for length and content. For further information, please contact the cited source.